Estradiol
updated
Estradiol is an estrogen hormone used to treat estrogen deficiency and menopausal symptoms. Tablets, patches, vaginal products and injections differ in absorption, dosing and side effects.
Estrogen receptor agonist
- Endogenous 17-beta estrogen
- Oral, transdermal, vaginal, and injectable products differ
- Estradiol valerate and cypionate are distinct ester prodrugs
What is estradiol used for?
Prescription estradiol treats menopausal symptoms and specific causes of estrogen deficiency. Some products are also approved to prevent osteoporosis in selected postmenopausal women. The indication and formulation determine which dosing instructions and safety data apply.
| Clinical question | Relevant product record | Endpoint that matters |
|---|---|---|
| Hot flashes from menopause | Oral, transdermal, or certain injected products with that indication | Symptom frequency and severity |
| Vulvovaginal atrophy only | Topical vaginal product is considered first in systemic labels | Local symptoms and tolerability |
| Hypoestrogenism | Product with the matching labeled cause and route | Replacement goal, symptoms, bone health, and safety |
| Chronic-disease prevention | No estradiol product should be inferred from a generic hormone claim | Clinical events, with exact molecule and regimen named |
Oral estradiol label · May 2025
FDA prescribing information
Preferred Pharmaceuticals. Estradiol tablets, USP. DailyMed record updated May 2025.
Defines oral micronized estradiol, its labeled menopause, hypoestrogenism, osteoporosis-prevention, and palliative uses, plus systemic warnings and CYP3A4 interactions.
- Participants / model
- People in the product's labeled menopause, hypoestrogenism, or narrow palliative-use groups
- Treatment
- Oral micronized 17-beta estradiol tablet
- Follow-up
- Current DailyMed record updated May 2025
- Study design
- Regulatory prescribing information
This is a repackaged generic label. WHI data quoted in it concern conjugated estrogens, not oral micronized estradiol.
Read the original sourceSystemic patch label
FDA prescribing information
Estradiol Transdermal System prescribing information. DailyMed; label revised December 2023.
Defines a systemic transdermal estradiol product for named menopause, hypoestrogenism, and osteoporosis-prevention uses with product-specific administration and class warnings.
- Participants / model
- Postmenopausal people and people with specified causes of hypoestrogenism under the label
- Treatment
- Systemic 17-beta estradiol transdermal patch
- Record date
- Label revised December 2023
- Study design
- Regulatory prescribing information
This record does not establish equivalence to oral, vaginal, or injectable estradiol.
Read the original source10 mcg vaginal insert label · June 2025
FDA prescribing information
Glenmark Pharmaceuticals. Estradiol vaginal inserts, USP. Revised June 2025.
Defines the atrophic-vaginitis indication, 10 mcg intravaginal schedule, systemic-absorption warning, contraindications, and common adverse reactions.
- Participants / model
- Postmenopausal people with atrophic vaginitis under the label
- Treatment
- 10 mcg estradiol vaginal insert
- Follow-up
- Label revised June 2025
- Study design
- Regulatory prescribing information
The label reports systemic absorption despite local vaginal administration.
Read the original sourceDelestrogen label · valerate IM oil
FDA prescribing information
JHP Pharmaceuticals. DELESTROGEN (estradiol valerate injection, USP). DailyMed.
Identifies estradiol valerate as an intramuscular oil product for named menopausal and hypoestrogenism indications and documents systemic estrogen warnings and CYP3A4 interactions.
- Participants / model
- People with the product's labeled menopause or hypoestrogenism indications
- Treatment
- Intramuscular estradiol valerate in oil
- Study design
- Regulatory prescribing information
Valerate is an ester product and should not inherit cypionate release or dosing claims.
Read the original sourceDepo-Estradiol label · cypionate IM oil
FDA prescribing information
Pfizer. DEPO-ESTRADIOL (estradiol cypionate injection, USP). DailyMed record updated February 2024.
Identifies estradiol cypionate in cottonseed oil for intramuscular use and its labeled vasomotor-symptom and hypogonadism indications.
- Participants / model
- People with the product's labeled menopausal vasomotor symptoms or hypoestrogenism due to hypogonadism
- Treatment
- Intramuscular estradiol cypionate in cottonseed oil
- Follow-up
- DailyMed record updated February 2024
- Study design
- Regulatory prescribing information
The label describes weeks of estrogenic effect after injection, but this does not create a dose conversion to valerate or non-injectable products.
Read the original sourceAre oral, patch, vaginal, valerate, and cypionate products interchangeable?
No. Unesterified 17-beta estradiol appears in oral tablets, systemic patches, and vaginal inserts. Estradiol valerate and estradiol cypionate are separate ester molecules in intramuscular oil products. They differ in labeled indications, delivery, concentration-time profile, excipients, and handling.
| Record | Route and identity | Approved use in the cited label |
|---|---|---|
| Estradiol tablet | Oral micronized 17-beta estradiol | Menopausal symptoms, hypoestrogenism, osteoporosis prevention in selected women, and narrow palliative uses |
| Estradiol transdermal system | Systemic 17-beta estradiol patch | Menopausal symptoms, hypoestrogenism, and selected osteoporosis prevention |
| Estradiol vaginal insert | 10 mcg intravaginal estradiol | Atrophic vaginitis due to menopause |
| Delestrogen | Estradiol valerate in oil, intramuscular | Menopausal symptoms and hypoestrogenism |
| Depo-Estradiol | Estradiol cypionate in cottonseed oil, intramuscular | Menopausal vasomotor symptoms and hypoestrogenism due to hypogonadism |
A vaginal route does not mean zero systemic exposure. The cited insert label explicitly says systemic absorption occurs and says systemic estrogen warnings must be considered.
Oral estradiol label · May 2025
FDA prescribing information
Preferred Pharmaceuticals. Estradiol tablets, USP. DailyMed record updated May 2025.
Defines oral micronized estradiol, its labeled menopause, hypoestrogenism, osteoporosis-prevention, and palliative uses, plus systemic warnings and CYP3A4 interactions.
- Participants / model
- People in the product's labeled menopause, hypoestrogenism, or narrow palliative-use groups
- Treatment
- Oral micronized 17-beta estradiol tablet
- Follow-up
- Current DailyMed record updated May 2025
- Study design
- Regulatory prescribing information
This is a repackaged generic label. WHI data quoted in it concern conjugated estrogens, not oral micronized estradiol.
Read the original sourceSystemic patch label
FDA prescribing information
Estradiol Transdermal System prescribing information. DailyMed; label revised December 2023.
Defines a systemic transdermal estradiol product for named menopause, hypoestrogenism, and osteoporosis-prevention uses with product-specific administration and class warnings.
- Participants / model
- Postmenopausal people and people with specified causes of hypoestrogenism under the label
- Treatment
- Systemic 17-beta estradiol transdermal patch
- Record date
- Label revised December 2023
- Study design
- Regulatory prescribing information
This record does not establish equivalence to oral, vaginal, or injectable estradiol.
Read the original source10 mcg vaginal insert label · June 2025
FDA prescribing information
Glenmark Pharmaceuticals. Estradiol vaginal inserts, USP. Revised June 2025.
Defines the atrophic-vaginitis indication, 10 mcg intravaginal schedule, systemic-absorption warning, contraindications, and common adverse reactions.
- Participants / model
- Postmenopausal people with atrophic vaginitis under the label
- Treatment
- 10 mcg estradiol vaginal insert
- Follow-up
- Label revised June 2025
- Study design
- Regulatory prescribing information
The label reports systemic absorption despite local vaginal administration.
Read the original sourceDelestrogen label · valerate IM oil
FDA prescribing information
JHP Pharmaceuticals. DELESTROGEN (estradiol valerate injection, USP). DailyMed.
Identifies estradiol valerate as an intramuscular oil product for named menopausal and hypoestrogenism indications and documents systemic estrogen warnings and CYP3A4 interactions.
- Participants / model
- People with the product's labeled menopause or hypoestrogenism indications
- Treatment
- Intramuscular estradiol valerate in oil
- Study design
- Regulatory prescribing information
Valerate is an ester product and should not inherit cypionate release or dosing claims.
Read the original sourceDepo-Estradiol label · cypionate IM oil
FDA prescribing information
Pfizer. DEPO-ESTRADIOL (estradiol cypionate injection, USP). DailyMed record updated February 2024.
Identifies estradiol cypionate in cottonseed oil for intramuscular use and its labeled vasomotor-symptom and hypogonadism indications.
- Participants / model
- People with the product's labeled menopausal vasomotor symptoms or hypoestrogenism due to hypogonadism
- Treatment
- Intramuscular estradiol cypionate in cottonseed oil
- Follow-up
- DailyMed record updated February 2024
- Study design
- Regulatory prescribing information
The label describes weeks of estrogenic effect after injection, but this does not create a dose conversion to valerate or non-injectable products.
Read the original sourceWhat can estradiol treat in menopause?
Systemic oral and transdermal products are labeled for moderate to severe vasomotor symptoms. Their labels also include moderate to severe vulvar and vaginal symptoms, while telling prescribers to consider a topical vaginal product first when those local symptoms are the only reason for treatment. The cited vaginal insert is specifically labeled for atrophic vaginitis due to menopause.
Some systemic labels include prevention of postmenopausal osteoporosis for selected women when non-estrogen medicines are not appropriate. That is a narrower decision than using estrogen broadly for chronic-disease prevention, which the labels reject.
Benefits and adverse effects should be revisited periodically. The patch label says to use the lowest effective dose for the shortest duration consistent with the individual's treatment goals and risks, and to try tapering or stopping at 3- to 6-month intervals for its vasomotor-symptom regimen.
Oral estradiol label · May 2025
FDA prescribing information
Preferred Pharmaceuticals. Estradiol tablets, USP. DailyMed record updated May 2025.
Defines oral micronized estradiol, its labeled menopause, hypoestrogenism, osteoporosis-prevention, and palliative uses, plus systemic warnings and CYP3A4 interactions.
- Participants / model
- People in the product's labeled menopause, hypoestrogenism, or narrow palliative-use groups
- Treatment
- Oral micronized 17-beta estradiol tablet
- Follow-up
- Current DailyMed record updated May 2025
- Study design
- Regulatory prescribing information
This is a repackaged generic label. WHI data quoted in it concern conjugated estrogens, not oral micronized estradiol.
Read the original sourceSystemic patch label
FDA prescribing information
Estradiol Transdermal System prescribing information. DailyMed; label revised December 2023.
Defines a systemic transdermal estradiol product for named menopause, hypoestrogenism, and osteoporosis-prevention uses with product-specific administration and class warnings.
- Participants / model
- Postmenopausal people and people with specified causes of hypoestrogenism under the label
- Treatment
- Systemic 17-beta estradiol transdermal patch
- Record date
- Label revised December 2023
- Study design
- Regulatory prescribing information
This record does not establish equivalence to oral, vaginal, or injectable estradiol.
Read the original source10 mcg vaginal insert label · June 2025
FDA prescribing information
Glenmark Pharmaceuticals. Estradiol vaginal inserts, USP. Revised June 2025.
Defines the atrophic-vaginitis indication, 10 mcg intravaginal schedule, systemic-absorption warning, contraindications, and common adverse reactions.
- Participants / model
- Postmenopausal people with atrophic vaginitis under the label
- Treatment
- 10 mcg estradiol vaginal insert
- Follow-up
- Label revised June 2025
- Study design
- Regulatory prescribing information
The label reports systemic absorption despite local vaginal administration.
Read the original sourceWhen is a progestogen needed with estradiol?
Systemic estrogen alone increases the risk of endometrial cancer in women who still have a uterus. Adding a progestogen reduces endometrial hyperplasia, which can precede cancer. Women who have had a hysterectomy generally do not need this protection, although residual endometriosis can change that decision.
The exact concurrent-hormone choice matters too. A risk estimate for one estrogen plus one progestogen is not automatically an estimate for estradiol alone or a different progestogen.
Oral estradiol label · May 2025
FDA prescribing information
Preferred Pharmaceuticals. Estradiol tablets, USP. DailyMed record updated May 2025.
Defines oral micronized estradiol, its labeled menopause, hypoestrogenism, osteoporosis-prevention, and palliative uses, plus systemic warnings and CYP3A4 interactions.
- Participants / model
- People in the product's labeled menopause, hypoestrogenism, or narrow palliative-use groups
- Treatment
- Oral micronized 17-beta estradiol tablet
- Follow-up
- Current DailyMed record updated May 2025
- Study design
- Regulatory prescribing information
This is a repackaged generic label. WHI data quoted in it concern conjugated estrogens, not oral micronized estradiol.
Read the original sourceSystemic patch label
FDA prescribing information
Estradiol Transdermal System prescribing information. DailyMed; label revised December 2023.
Defines a systemic transdermal estradiol product for named menopause, hypoestrogenism, and osteoporosis-prevention uses with product-specific administration and class warnings.
- Participants / model
- Postmenopausal people and people with specified causes of hypoestrogenism under the label
- Treatment
- Systemic 17-beta estradiol transdermal patch
- Record date
- Label revised December 2023
- Study design
- Regulatory prescribing information
This record does not establish equivalence to oral, vaginal, or injectable estradiol.
Read the original source10 mcg vaginal insert label · June 2025
FDA prescribing information
Glenmark Pharmaceuticals. Estradiol vaginal inserts, USP. Revised June 2025.
Defines the atrophic-vaginitis indication, 10 mcg intravaginal schedule, systemic-absorption warning, contraindications, and common adverse reactions.
- Participants / model
- Postmenopausal people with atrophic vaginitis under the label
- Treatment
- 10 mcg estradiol vaginal insert
- Follow-up
- Label revised June 2025
- Study design
- Regulatory prescribing information
The label reports systemic absorption despite local vaginal administration.
Read the original sourceDoes the route change venous-thromboembolism risk?
ESTHER provides observational route-specific estimates. It compared 271 postmenopausal women aged 45 to 70 with a first idiopathic venous thromboembolism with 610 controls. Compared with nonuse, current oral estrogen use had an adjusted odds ratio of 4.2, with a 95% confidence interval of 1.5 to 11.6; transdermal estrogen had an odds ratio of 0.9, with a confidence interval of 0.4 to 2.1.
ESTHER was an observational study in postmenopausal women, not a randomized trial. Its results do not establish that patches are risk-free or estimate the risk of injected estradiol, vaginal products or other doses.
The labels also treat active or prior deep-vein thrombosis or pulmonary embolism and active or prior arterial thromboembolic disease as contraindications for the cited products. Individual risk factors and upcoming immobilization or surgery matter.
ESTHER · Circulation 2007
Case-control study
Canonico M et al. Circulation. 2007;115(7):840-845. doi:10.1161/CIRCULATIONAHA.106.642280. PMID: 17309934.
Oral estrogen use was associated with higher odds of first idiopathic VTE, while the estimate for transdermal estrogen was near null in this postmenopausal case-control population.
- Participants / model
- Postmenopausal women aged 45 to 70 in France; 271 first idiopathic VTE cases and 610 controls
- Treatment
- Observed current oral or transdermal estrogen use, with progestogen context
- Follow-up
- Exposure assessed for cases recruited from 1999 through 2005
- Study design
- Multicenter observational case-control study
- Funding
- Public and nonprofit sources reported in the article
Association is not randomized causation and does not establish zero transdermal risk or transfer directly to other populations or products.
Read the original sourceOral estradiol label · May 2025
FDA prescribing information
Preferred Pharmaceuticals. Estradiol tablets, USP. DailyMed record updated May 2025.
Defines oral micronized estradiol, its labeled menopause, hypoestrogenism, osteoporosis-prevention, and palliative uses, plus systemic warnings and CYP3A4 interactions.
- Participants / model
- People in the product's labeled menopause, hypoestrogenism, or narrow palliative-use groups
- Treatment
- Oral micronized 17-beta estradiol tablet
- Follow-up
- Current DailyMed record updated May 2025
- Study design
- Regulatory prescribing information
This is a repackaged generic label. WHI data quoted in it concern conjugated estrogens, not oral micronized estradiol.
Read the original sourceSystemic patch label
FDA prescribing information
Estradiol Transdermal System prescribing information. DailyMed; label revised December 2023.
Defines a systemic transdermal estradiol product for named menopause, hypoestrogenism, and osteoporosis-prevention uses with product-specific administration and class warnings.
- Participants / model
- Postmenopausal people and people with specified causes of hypoestrogenism under the label
- Treatment
- Systemic 17-beta estradiol transdermal patch
- Record date
- Label revised December 2023
- Study design
- Regulatory prescribing information
This record does not establish equivalence to oral, vaginal, or injectable estradiol.
Read the original source10 mcg vaginal insert label · June 2025
FDA prescribing information
Glenmark Pharmaceuticals. Estradiol vaginal inserts, USP. Revised June 2025.
Defines the atrophic-vaginitis indication, 10 mcg intravaginal schedule, systemic-absorption warning, contraindications, and common adverse reactions.
- Participants / model
- Postmenopausal people with atrophic vaginitis under the label
- Treatment
- 10 mcg estradiol vaginal insert
- Follow-up
- Label revised June 2025
- Study design
- Regulatory prescribing information
The label reports systemic absorption despite local vaginal administration.
Read the original sourceWhat does the small route crossover trial actually prove?
In 21 postmenopausal women, eight weeks of transdermal estradiol did not change C-reactive protein or IGF-1, while oral conjugated equine estrogen more than doubled C-reactive protein and reduced IGF-1. The result supports a hepatic first-pass distinction. It is not a head-to-head trial of oral versus transdermal estradiol, and it measured biomarkers rather than heart attacks, strokes, or blood clots.
Route-marker crossover · JACC 2003
Randomized crossover biomarker trial
Vongpatanasin W et al. Journal of the American College of Cardiology. 2003;41(8):1358-1363. doi:10.1016/S0735-1097(03)00156-6. PMID: 12706932.
In 21 postmenopausal women, transdermal estradiol did not change CRP or IGF-1 while oral conjugated estrogen increased CRP and reduced IGF-1 over eight weeks.
- Participants / model
- 21 postmenopausal women
- Treatment
- Transdermal 17-beta estradiol, oral conjugated equine estrogen, and placebo in crossover periods
- Follow-up
- Eight weeks per treatment
- Study design
- Randomized placebo-controlled crossover biomarker study
- Funding
- US Public Health Service support indexed by PubMed
The oral arm was conjugated equine estrogen, not oral estradiol, and outcomes were biomarkers rather than clinical events.
Read the original sourceDo Women's Health Initiative numbers describe estradiol itself?
Not directly. The major Women's Health Initiative regimens cited in estradiol labels used oral conjugated estrogens, either alone or with medroxyprogesterone acetate. Those trials inform class warnings and clinical caution, but they were not trials of oral micronized estradiol, a patch, a vaginal insert, estradiol valerate, or estradiol cypionate.
Current patch and vaginal-insert warnings state that the relevance of WHI findings to other doses, routes, estrogens, and progestogens is unknown. Conjugated-estrogen event rates therefore are not estradiol-specific estimates.
Oral estradiol label · May 2025
FDA prescribing information
Preferred Pharmaceuticals. Estradiol tablets, USP. DailyMed record updated May 2025.
Defines oral micronized estradiol, its labeled menopause, hypoestrogenism, osteoporosis-prevention, and palliative uses, plus systemic warnings and CYP3A4 interactions.
- Participants / model
- People in the product's labeled menopause, hypoestrogenism, or narrow palliative-use groups
- Treatment
- Oral micronized 17-beta estradiol tablet
- Follow-up
- Current DailyMed record updated May 2025
- Study design
- Regulatory prescribing information
This is a repackaged generic label. WHI data quoted in it concern conjugated estrogens, not oral micronized estradiol.
Read the original sourceSystemic patch label
FDA prescribing information
Estradiol Transdermal System prescribing information. DailyMed; label revised December 2023.
Defines a systemic transdermal estradiol product for named menopause, hypoestrogenism, and osteoporosis-prevention uses with product-specific administration and class warnings.
- Participants / model
- Postmenopausal people and people with specified causes of hypoestrogenism under the label
- Treatment
- Systemic 17-beta estradiol transdermal patch
- Record date
- Label revised December 2023
- Study design
- Regulatory prescribing information
This record does not establish equivalence to oral, vaginal, or injectable estradiol.
Read the original source10 mcg vaginal insert label · June 2025
FDA prescribing information
Glenmark Pharmaceuticals. Estradiol vaginal inserts, USP. Revised June 2025.
Defines the atrophic-vaginitis indication, 10 mcg intravaginal schedule, systemic-absorption warning, contraindications, and common adverse reactions.
- Participants / model
- Postmenopausal people with atrophic vaginitis under the label
- Treatment
- 10 mcg estradiol vaginal insert
- Follow-up
- Label revised June 2025
- Study design
- Regulatory prescribing information
The label reports systemic absorption despite local vaginal administration.
Read the original sourceWhich safety checks and interactions are easy to miss?
The five U.S. labels share serious cardiovascular, thromboembolic, cancer, gallbladder, and other class warnings, but exact contraindications and adverse effects belong to the product. Common adverse effects can include headache, breast tenderness or pain, bleeding changes, nausea, application-site reactions for patches, and local irritation or infection findings with vaginal products.
- CYP3A4 inducers such as rifampin, carbamazepine, phenobarbital, and St. John's wort can lower estrogen concentrations and effect; inhibitors can increase concentrations and adverse effects.
- Estrogen can raise thyroid-binding globulin. A person taking thyroid replacement may need thyroid-function monitoring and adjustment.
- Severe hypertriglyceridemia, liver disease or cholestatic jaundice history, gallbladder disease, fluid retention, migraine, endometriosis, and hereditary angioedema can change the risk discussion.
- Pregnancy, unexplained bleeding, estrogen-dependent cancer, and clot history appear in the cited contraindication lists, with wording that must be read from the actual product label.
Oral estradiol label · May 2025
FDA prescribing information
Preferred Pharmaceuticals. Estradiol tablets, USP. DailyMed record updated May 2025.
Defines oral micronized estradiol, its labeled menopause, hypoestrogenism, osteoporosis-prevention, and palliative uses, plus systemic warnings and CYP3A4 interactions.
- Participants / model
- People in the product's labeled menopause, hypoestrogenism, or narrow palliative-use groups
- Treatment
- Oral micronized 17-beta estradiol tablet
- Follow-up
- Current DailyMed record updated May 2025
- Study design
- Regulatory prescribing information
This is a repackaged generic label. WHI data quoted in it concern conjugated estrogens, not oral micronized estradiol.
Read the original sourceSystemic patch label
FDA prescribing information
Estradiol Transdermal System prescribing information. DailyMed; label revised December 2023.
Defines a systemic transdermal estradiol product for named menopause, hypoestrogenism, and osteoporosis-prevention uses with product-specific administration and class warnings.
- Participants / model
- Postmenopausal people and people with specified causes of hypoestrogenism under the label
- Treatment
- Systemic 17-beta estradiol transdermal patch
- Record date
- Label revised December 2023
- Study design
- Regulatory prescribing information
This record does not establish equivalence to oral, vaginal, or injectable estradiol.
Read the original source10 mcg vaginal insert label · June 2025
FDA prescribing information
Glenmark Pharmaceuticals. Estradiol vaginal inserts, USP. Revised June 2025.
Defines the atrophic-vaginitis indication, 10 mcg intravaginal schedule, systemic-absorption warning, contraindications, and common adverse reactions.
- Participants / model
- Postmenopausal people with atrophic vaginitis under the label
- Treatment
- 10 mcg estradiol vaginal insert
- Follow-up
- Label revised June 2025
- Study design
- Regulatory prescribing information
The label reports systemic absorption despite local vaginal administration.
Read the original sourceDelestrogen label · valerate IM oil
FDA prescribing information
JHP Pharmaceuticals. DELESTROGEN (estradiol valerate injection, USP). DailyMed.
Identifies estradiol valerate as an intramuscular oil product for named menopausal and hypoestrogenism indications and documents systemic estrogen warnings and CYP3A4 interactions.
- Participants / model
- People with the product's labeled menopause or hypoestrogenism indications
- Treatment
- Intramuscular estradiol valerate in oil
- Study design
- Regulatory prescribing information
Valerate is an ester product and should not inherit cypionate release or dosing claims.
Read the original sourceDepo-Estradiol label · cypionate IM oil
FDA prescribing information
Pfizer. DEPO-ESTRADIOL (estradiol cypionate injection, USP). DailyMed record updated February 2024.
Identifies estradiol cypionate in cottonseed oil for intramuscular use and its labeled vasomotor-symptom and hypogonadism indications.
- Participants / model
- People with the product's labeled menopausal vasomotor symptoms or hypoestrogenism due to hypogonadism
- Treatment
- Intramuscular estradiol cypionate in cottonseed oil
- Follow-up
- DailyMed record updated February 2024
- Study design
- Regulatory prescribing information
The label describes weeks of estrogenic effect after injection, but this does not create a dose conversion to valerate or non-injectable products.
Read the original sourceWhat stays the same across estradiol products?
Estradiol binds estrogen receptors in responsive tissues and participates in pituitary feedback on luteinizing hormone and follicle-stimulating hormone. Delivery changes exposure: oral estradiol enters hepatic first-pass handling, a patch supplies systemic hormone through skin, a vaginal insert is locally administered with some systemic absorption, and injected esters must first release estradiol from their depot and ester form.
Oral estradiol label · May 2025
FDA prescribing information
Preferred Pharmaceuticals. Estradiol tablets, USP. DailyMed record updated May 2025.
Defines oral micronized estradiol, its labeled menopause, hypoestrogenism, osteoporosis-prevention, and palliative uses, plus systemic warnings and CYP3A4 interactions.
- Participants / model
- People in the product's labeled menopause, hypoestrogenism, or narrow palliative-use groups
- Treatment
- Oral micronized 17-beta estradiol tablet
- Follow-up
- Current DailyMed record updated May 2025
- Study design
- Regulatory prescribing information
This is a repackaged generic label. WHI data quoted in it concern conjugated estrogens, not oral micronized estradiol.
Read the original sourceSystemic patch label
FDA prescribing information
Estradiol Transdermal System prescribing information. DailyMed; label revised December 2023.
Defines a systemic transdermal estradiol product for named menopause, hypoestrogenism, and osteoporosis-prevention uses with product-specific administration and class warnings.
- Participants / model
- Postmenopausal people and people with specified causes of hypoestrogenism under the label
- Treatment
- Systemic 17-beta estradiol transdermal patch
- Record date
- Label revised December 2023
- Study design
- Regulatory prescribing information
This record does not establish equivalence to oral, vaginal, or injectable estradiol.
Read the original source10 mcg vaginal insert label · June 2025
FDA prescribing information
Glenmark Pharmaceuticals. Estradiol vaginal inserts, USP. Revised June 2025.
Defines the atrophic-vaginitis indication, 10 mcg intravaginal schedule, systemic-absorption warning, contraindications, and common adverse reactions.
- Participants / model
- Postmenopausal people with atrophic vaginitis under the label
- Treatment
- 10 mcg estradiol vaginal insert
- Follow-up
- Label revised June 2025
- Study design
- Regulatory prescribing information
The label reports systemic absorption despite local vaginal administration.
Read the original sourceDelestrogen label · valerate IM oil
FDA prescribing information
JHP Pharmaceuticals. DELESTROGEN (estradiol valerate injection, USP). DailyMed.
Identifies estradiol valerate as an intramuscular oil product for named menopausal and hypoestrogenism indications and documents systemic estrogen warnings and CYP3A4 interactions.
- Participants / model
- People with the product's labeled menopause or hypoestrogenism indications
- Treatment
- Intramuscular estradiol valerate in oil
- Study design
- Regulatory prescribing information
Valerate is an ester product and should not inherit cypionate release or dosing claims.
Read the original sourceDepo-Estradiol label · cypionate IM oil
FDA prescribing information
Pfizer. DEPO-ESTRADIOL (estradiol cypionate injection, USP). DailyMed record updated February 2024.
Identifies estradiol cypionate in cottonseed oil for intramuscular use and its labeled vasomotor-symptom and hypogonadism indications.
- Participants / model
- People with the product's labeled menopausal vasomotor symptoms or hypoestrogenism due to hypogonadism
- Treatment
- Intramuscular estradiol cypionate in cottonseed oil
- Follow-up
- DailyMed record updated February 2024
- Study design
- Regulatory prescribing information
The label describes weeks of estrogenic effect after injection, but this does not create a dose conversion to valerate or non-injectable products.
Read the original sourceWhich studies and labels support these answers?
Five product labels cover formulation, approved uses, dosing and warnings. ESTHER examined blood-clot risk in postmenopausal women. The small crossover trial compared blood markers after transdermal estradiol and oral conjugated equine estrogen.
Oral estradiol label · May 2025
FDA prescribing information
Preferred Pharmaceuticals. Estradiol tablets, USP. DailyMed record updated May 2025.
Defines oral micronized estradiol, its labeled menopause, hypoestrogenism, osteoporosis-prevention, and palliative uses, plus systemic warnings and CYP3A4 interactions.
- Participants / model
- People in the product's labeled menopause, hypoestrogenism, or narrow palliative-use groups
- Treatment
- Oral micronized 17-beta estradiol tablet
- Follow-up
- Current DailyMed record updated May 2025
- Study design
- Regulatory prescribing information
This is a repackaged generic label. WHI data quoted in it concern conjugated estrogens, not oral micronized estradiol.
Read the original sourceSystemic patch label
FDA prescribing information
Estradiol Transdermal System prescribing information. DailyMed; label revised December 2023.
Defines a systemic transdermal estradiol product for named menopause, hypoestrogenism, and osteoporosis-prevention uses with product-specific administration and class warnings.
- Participants / model
- Postmenopausal people and people with specified causes of hypoestrogenism under the label
- Treatment
- Systemic 17-beta estradiol transdermal patch
- Record date
- Label revised December 2023
- Study design
- Regulatory prescribing information
This record does not establish equivalence to oral, vaginal, or injectable estradiol.
Read the original source10 mcg vaginal insert label · June 2025
FDA prescribing information
Glenmark Pharmaceuticals. Estradiol vaginal inserts, USP. Revised June 2025.
Defines the atrophic-vaginitis indication, 10 mcg intravaginal schedule, systemic-absorption warning, contraindications, and common adverse reactions.
- Participants / model
- Postmenopausal people with atrophic vaginitis under the label
- Treatment
- 10 mcg estradiol vaginal insert
- Follow-up
- Label revised June 2025
- Study design
- Regulatory prescribing information
The label reports systemic absorption despite local vaginal administration.
Read the original sourceDelestrogen label · valerate IM oil
FDA prescribing information
JHP Pharmaceuticals. DELESTROGEN (estradiol valerate injection, USP). DailyMed.
Identifies estradiol valerate as an intramuscular oil product for named menopausal and hypoestrogenism indications and documents systemic estrogen warnings and CYP3A4 interactions.
- Participants / model
- People with the product's labeled menopause or hypoestrogenism indications
- Treatment
- Intramuscular estradiol valerate in oil
- Study design
- Regulatory prescribing information
Valerate is an ester product and should not inherit cypionate release or dosing claims.
Read the original sourceDepo-Estradiol label · cypionate IM oil
FDA prescribing information
Pfizer. DEPO-ESTRADIOL (estradiol cypionate injection, USP). DailyMed record updated February 2024.
Identifies estradiol cypionate in cottonseed oil for intramuscular use and its labeled vasomotor-symptom and hypogonadism indications.
- Participants / model
- People with the product's labeled menopausal vasomotor symptoms or hypoestrogenism due to hypogonadism
- Treatment
- Intramuscular estradiol cypionate in cottonseed oil
- Follow-up
- DailyMed record updated February 2024
- Study design
- Regulatory prescribing information
The label describes weeks of estrogenic effect after injection, but this does not create a dose conversion to valerate or non-injectable products.
Read the original sourceESTHER · Circulation 2007
Case-control study
Canonico M et al. Circulation. 2007;115(7):840-845. doi:10.1161/CIRCULATIONAHA.106.642280. PMID: 17309934.
Oral estrogen use was associated with higher odds of first idiopathic VTE, while the estimate for transdermal estrogen was near null in this postmenopausal case-control population.
- Participants / model
- Postmenopausal women aged 45 to 70 in France; 271 first idiopathic VTE cases and 610 controls
- Treatment
- Observed current oral or transdermal estrogen use, with progestogen context
- Follow-up
- Exposure assessed for cases recruited from 1999 through 2005
- Study design
- Multicenter observational case-control study
- Funding
- Public and nonprofit sources reported in the article
Association is not randomized causation and does not establish zero transdermal risk or transfer directly to other populations or products.
Read the original sourceRoute-marker crossover · JACC 2003
Randomized crossover biomarker trial
Vongpatanasin W et al. Journal of the American College of Cardiology. 2003;41(8):1358-1363. doi:10.1016/S0735-1097(03)00156-6. PMID: 12706932.
In 21 postmenopausal women, transdermal estradiol did not change CRP or IGF-1 while oral conjugated estrogen increased CRP and reduced IGF-1 over eight weeks.
- Participants / model
- 21 postmenopausal women
- Treatment
- Transdermal 17-beta estradiol, oral conjugated equine estrogen, and placebo in crossover periods
- Follow-up
- Eight weeks per treatment
- Study design
- Randomized placebo-controlled crossover biomarker study
- Funding
- US Public Health Service support indexed by PubMed
The oral arm was conjugated equine estrogen, not oral estradiol, and outcomes were biomarkers rather than clinical events.
Read the original sourceStudies and sources
Oral estradiol label · May 2025
FDA prescribing information
Preferred Pharmaceuticals. Estradiol tablets, USP. DailyMed record updated May 2025.
Defines oral micronized estradiol, its labeled menopause, hypoestrogenism, osteoporosis-prevention, and palliative uses, plus systemic warnings and CYP3A4 interactions.
- Participants / model
- People in the product's labeled menopause, hypoestrogenism, or narrow palliative-use groups
- Treatment
- Oral micronized 17-beta estradiol tablet
- Follow-up
- Current DailyMed record updated May 2025
- Study design
- Regulatory prescribing information
This is a repackaged generic label. WHI data quoted in it concern conjugated estrogens, not oral micronized estradiol.
Read the original sourceSystemic patch label
FDA prescribing information
Estradiol Transdermal System prescribing information. DailyMed; label revised December 2023.
Defines a systemic transdermal estradiol product for named menopause, hypoestrogenism, and osteoporosis-prevention uses with product-specific administration and class warnings.
- Participants / model
- Postmenopausal people and people with specified causes of hypoestrogenism under the label
- Treatment
- Systemic 17-beta estradiol transdermal patch
- Record date
- Label revised December 2023
- Study design
- Regulatory prescribing information
This record does not establish equivalence to oral, vaginal, or injectable estradiol.
Read the original source10 mcg vaginal insert label · June 2025
FDA prescribing information
Glenmark Pharmaceuticals. Estradiol vaginal inserts, USP. Revised June 2025.
Defines the atrophic-vaginitis indication, 10 mcg intravaginal schedule, systemic-absorption warning, contraindications, and common adverse reactions.
- Participants / model
- Postmenopausal people with atrophic vaginitis under the label
- Treatment
- 10 mcg estradiol vaginal insert
- Follow-up
- Label revised June 2025
- Study design
- Regulatory prescribing information
The label reports systemic absorption despite local vaginal administration.
Read the original sourceDelestrogen label · valerate IM oil
FDA prescribing information
JHP Pharmaceuticals. DELESTROGEN (estradiol valerate injection, USP). DailyMed.
Identifies estradiol valerate as an intramuscular oil product for named menopausal and hypoestrogenism indications and documents systemic estrogen warnings and CYP3A4 interactions.
- Participants / model
- People with the product's labeled menopause or hypoestrogenism indications
- Treatment
- Intramuscular estradiol valerate in oil
- Study design
- Regulatory prescribing information
Valerate is an ester product and should not inherit cypionate release or dosing claims.
Read the original sourceDepo-Estradiol label · cypionate IM oil
FDA prescribing information
Pfizer. DEPO-ESTRADIOL (estradiol cypionate injection, USP). DailyMed record updated February 2024.
Identifies estradiol cypionate in cottonseed oil for intramuscular use and its labeled vasomotor-symptom and hypogonadism indications.
- Participants / model
- People with the product's labeled menopausal vasomotor symptoms or hypoestrogenism due to hypogonadism
- Treatment
- Intramuscular estradiol cypionate in cottonseed oil
- Follow-up
- DailyMed record updated February 2024
- Study design
- Regulatory prescribing information
The label describes weeks of estrogenic effect after injection, but this does not create a dose conversion to valerate or non-injectable products.
Read the original sourceESTHER · Circulation 2007
Case-control study
Canonico M et al. Circulation. 2007;115(7):840-845. doi:10.1161/CIRCULATIONAHA.106.642280. PMID: 17309934.
Oral estrogen use was associated with higher odds of first idiopathic VTE, while the estimate for transdermal estrogen was near null in this postmenopausal case-control population.
- Participants / model
- Postmenopausal women aged 45 to 70 in France; 271 first idiopathic VTE cases and 610 controls
- Treatment
- Observed current oral or transdermal estrogen use, with progestogen context
- Follow-up
- Exposure assessed for cases recruited from 1999 through 2005
- Study design
- Multicenter observational case-control study
- Funding
- Public and nonprofit sources reported in the article
Association is not randomized causation and does not establish zero transdermal risk or transfer directly to other populations or products.
Read the original sourceRoute-marker crossover · JACC 2003
Randomized crossover biomarker trial
Vongpatanasin W et al. Journal of the American College of Cardiology. 2003;41(8):1358-1363. doi:10.1016/S0735-1097(03)00156-6. PMID: 12706932.
In 21 postmenopausal women, transdermal estradiol did not change CRP or IGF-1 while oral conjugated estrogen increased CRP and reduced IGF-1 over eight weeks.
- Participants / model
- 21 postmenopausal women
- Treatment
- Transdermal 17-beta estradiol, oral conjugated equine estrogen, and placebo in crossover periods
- Follow-up
- Eight weeks per treatment
- Study design
- Randomized placebo-controlled crossover biomarker study
- Funding
- US Public Health Service support indexed by PubMed
The oral arm was conjugated equine estrogen, not oral estradiol, and outcomes were biomarkers rather than clinical events.
Read the original sourceWhy is Estradiol in S tier?
The S tier reflects established prescription uses and direct clinical evidence. Benefits and risks remain specific to product, route, age, indication, concurrent hormones, and relevant anatomy; conjugated-estrogen trial rates are not estradiol-specific estimates.
read Estradiol in the reptides guide, chapter 11: 13 pages, free to read.